Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;36(9):760-763.
doi: 10.1080/09513590.2020.1739267. Epub 2020 Mar 11.

Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome

Michelle T Alves  1 , Isabella D P de Souza  1 , Cláudia N Ferreira  2 , Ana Lúcia Cândido  3 , Mariana F Bizzi  3 , Flávia R Oliveira  3   4 , Fernando M Reis  3 , Karina B Gomes  1
Affiliations
Free article

Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome

Michelle T Alves et al. Gynecol Endocrinol. 2020 Sep.
Free article

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder that affects women in reproductive age. This study aimed to evaluate Gal-3 levels and its role on metabolic parameters in women with PCOS. Gal-3 was measured in 44 PCOS and 25 women recruited as control group for the case-control study. Gal-3 levels were similar between PCOS and control groups (p > 0.05), but showed a positive correlation with glucose levels in the oral glucose tolerance test (OGTT) (r = 0.403, p = 0.037), body mass index (BMI) (r = 0.469, p = 0.027), insulin levels (r = 0.453, p = 0.030) and HOMA-IR (r = 0.738, p = 0.037) in PCOS group. The data suggest that Gal-3 plays a role in the pathophysiology of the insulin resistance and obesity in PCOS group.

Keywords: Polycystic ovary syndrome; galectin-3; glucose; insulin resistance; obesity.

PubMed Disclaimer

LinkOut - more resources